You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

IDH1

Showing 1 - 25 of 352
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cholangiocarcinoma With IDH1 Mutation, Solid Tumors With IDH1 Mutation Trial in Beijing (AB-218 capsule)

Not yet recruiting
  • Cholangiocarcinoma With IDH1 Mutation
  • Solid Tumors With IDH1 Mutation
  • AB-218 capsule
  • Beijing, Beijing, China
    Peking Union Medical College Hospital, Chinese Academy of Medica
Apr 2, 2023

IDH1-mutant Cholangiocarcinoma Trial (Ivosidenib, Recommended Combination Dose (RCD) of ivosidenib, Nivolumab)

Not yet recruiting
  • IDH1-mutant Cholangiocarcinoma
  • (no location specified)
Jun 29, 2023

Brain Tumor, Cancer Trial run by the National Cancer Institute (NCI) (Zotiraciclib)

Not yet recruiting
  • Brain Tumor
  • Cancer
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Glioma, Malignant, Computer-Assisted Trial in Shanghai (Validation of IDH1 mutations from the radiomics model)

Active, not recruiting
  • Glioma, Malignant
  • Computer-Assisted
  • Validation of IDH1 mutations from the radiomics model
  • Shanghai, Shanghai, China
    Huashan Hospital, Fudan University
Jul 23, 2023

Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic Trial (Ivosidenib)

Not yet recruiting
  • Cholangiocarcinoma Non-resectable
  • Cholangiocarcinoma Metastatic
  • (no location specified)
Oct 10, 2023

Low-grade Glioma, IDH2 Gene Mutation, Recurrent Glioma Trial in Boston (Niraparib, Resection/Treatment with Niraparib)

Recruiting
  • Low-grade Glioma
  • +4 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Oct 19, 2022

Recurrent IDH1/2 Mutated Glioma Trial in Paris (Azacitidine)

Recruiting
  • Recurrent IDH1/2 Mutated Glioma
  • Paris, France
    Pitie Salpetriere Hospital
Aug 29, 2022

Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1

Not yet recruiting
  • Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
  • Ivosidenib 500mg
  • Placebo
  • (no location specified)
Nov 7, 2023

Low Grade Glioma of Brain Trial in Durham (PEPIDH1M vaccine + vorasidenib)

Not yet recruiting
  • Low Grade Glioma of Brain
  • PEPIDH1M vaccine + vorasidenib
  • Durham, North Carolina
    Duke University Medical Center
Nov 2, 2022

Glioma Trial in Melbourne (Biopsy, Part A: AB-218, Surgery (maximal resection))

Recruiting
  • Glioma
  • Biopsy
  • +3 more
  • Melbourne, Victoria, Australia
    Royal Melbourne Hospital
Oct 11, 2022

Advanced Solid Tumor, IDH1 Mutation, Glioma Trial in Pittsburgh (ivosidenib and nivolumab)

Recruiting
  • Advanced Solid Tumor
  • +2 more
  • ivosidenib and nivolumab
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Mar 14, 2022

Acute Myeloid Leukemia (AML) Trial in United States (Gilteritinib, Ivosidenib, Enasidenib)

Not yet recruiting
  • Acute Myeloid Leukemia (AML)
  • Basking Ridge, New Jersey
  • +6 more
Mar 3, 2023

Acute Myeloid Leukemia (AML) Trial in Austria, Italy, Spain (Ivosidenib Oral Tablet, Azacitidine)

Not yet recruiting
  • Acute Myeloid Leukemia (AML)
  • Vienna, Austria
  • +3 more
Jun 8, 2023

MDS, Acute Myeloid Leukemia Trial in New Haven (AG-120, Nivolumab)

Withdrawn
  • Myelodysplastic Syndromes
  • Acute Myeloid Leukemia
  • New Haven, Connecticut
    Yale Cancer Center
Jan 6, 2022

Epilepsy; Seizure Trial (ES-481)

Withdrawn
  • Epilepsy; Seizure
  • (no location specified)
Mar 28, 2022

Glioma Trial (AB-218)

Not yet recruiting
  • Glioma
  • (no location specified)
Mar 29, 2022

Astrocytoma Trial (Vorasidenib, Pembrolizumab)

Not yet recruiting
  • Astrocytoma
  • (no location specified)
Aug 1, 2022

Glioma Trial in Tokyo (DS-1001b)

Active, not recruiting
  • Glioma
  • Tokyo, Japan
    National Cancer Center Hospital
Feb 2, 2022

Astrocytoma, Grade IV, Glioblastoma, Giant Cell Glioblastoma Trial in United States (CYNK-001 systemic and Intra cavity

Recruiting
  • Astrocytoma, Grade IV
  • +3 more
  • CYNK-001 systemic and Intra cavity administration
  • Duarte, California
  • +5 more
Jan 20, 2023

IDH1 Mutation Myeloid Tumors Trial in Baltimore, Boston, Columbus (Ivosidenib)

Active, not recruiting
  • IDH1 Mutation Myeloid Neoplasms
  • Baltimore, Maryland
  • +3 more
Oct 25, 2021

Glioma, Recurrence, Disease Attributes Trial (Vorasidenib)

Available
  • Glioma
  • +10 more
  • (no location specified)
Oct 19, 2022

Glioma Trial in United States (AG881)

Active, not recruiting
  • Glioma
  • Los Angeles, California
  • +8 more
May 16, 2022

Clonal Cytopenia of Undetermined Significance Trial in United States (Ivosidenib)

Recruiting
  • Clonal Cytopenia of Undetermined Significance
  • Rochester, Minnesota
  • +5 more
Apr 4, 2022

Clinical Evaluation of Genetron IDH1 PCR Kit in Glioma Patients

Completed
  • Glioma, Malignant
  • Glioma, Mixed
    • Jilin, China
    • +3 more
    Nov 12, 2021

    WHO Grade II Glioma Trial in Japan (DS-1001b)

    Active, not recruiting
    • WHO Grade II Glioma
    • Nagoya, Aichi, Japan
    • +10 more
    Feb 3, 2022